Back to results
US 2010/0247659 A1Published application
Phenylphthalimide analogs for treating diabetic macular edema
AssigneeCharlesson, LLC
InventorsDumitru Ionescu, CherylAnn Love, Danyang Chen, Ronald Andrew Wassel
Life of this patent
Estimating the term…
Abstract
Novel methods are provided to prevent blindness associated with diabetic macular edema by administration of a phenylphthalimide analog. Additionally, sustainability of the effect of administration of the phenylphthalimide analog is improved via encapsulation with poly(lactic-co-glycolic acid) nanoparticles. Finally, a novel method for synthesizing (2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione is disclosed.
Claims15
A method comprising:
- administering to a subject having retinal edema a pharmaceutical composition having the chemical structure:
A method comprising:
- providing a pharmaceutical composition to a patient experiencing retinal edema, the pharmaceutical composition comprising an agent having the chemical structure:
- encapsulated in a poly(lactic-co-glycolic acid) nanoparticle.
A method comprising:
- sustaining the efficacy of a pharmaceutical composition comprising a compound having the structure:
- by encapsulating the compound in a poly(lactic-co-glycolic acid) nanoparticle;
- wherein subsequent delivery of the encapsulated capsule causes the therapeutic effect of the compound for the treatment of diabetic macular edema to be extended.
A method comprising:
- synthesizing a composition of the formula
- by coupling 4-nitrophthalic anhydride and 2,6-diisopropyl aniline by refluxing in acetic acid to produce (2,6-diisopropylphenyl)-5-nitro-1H-isoindole-1,3-dione;
- and
- hydrogenating the (2,6-diisopropylphenyl)-5-nitro-4H-isoindole-1,3-dione by reacting the (2,6-diisopropylphenyl)-5-nitro-1H-isoindole-1,3-dione via a catalytic hydrogenation or transfer hydrogenation reaction.
1 more element
Dependencies are inferred from the claim text.